storer schreef op 8 februari 2021 07:16:
So...het nieuws is de aankondiging van geen nieuws, of toch niet iets wat er niet zat aan te komen.
Neemt nu wel de onzekerheid weg over waarom er pers conferentie zou zijn na data. Ik zou denken dat alles er zeer goed uitziet maar het wederom wachten is.
Geneva, Switzerland, February 08, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief" or the "Company") affirms that its collaboration partner NeuroRx, Inc. has initiated a phase 2/3 clinical trial investigating the role of inhaled RLF-100™ (aviptadil; ZYESAMI™) for the treatment of patients with severe COVID-19 in partnership with UCI Health of the University of California, Irvine. The objective of the current study is to determine whether RLF-100™, administered at the earlier (severe) stage of COVID-19 can reduce the likelihood of progression to critical COVID-19 with respiratory failure: the predominant cause of death in COVID-19-infected individuals. For further information, please refer to:
www.neurorxpharma.com/press-releases/... Furthermore, top-line data from the previously completed phase 2b/3 trial of the intravenous (“IV”) formulation of RLF-100™ are slated to be released this month. The statistical analysis of the data remains ongoing. Relief expects top-line data from this trial to be reported once the required statistical analyses have been completed.